TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, it has successfully engineered a genetically-modified (GM) host to generate analogs of Oragenics’ lead lantibiotic compound Mutacin 1140 (MU1140). The successful production of the first generation analogs using the GM host demonstrates significant progress and proof-of-concept toward the eventual production of a pipeline of novel antibiotics. The MU1140 analogs may offer superior antibacterial activity and pharmacologic properties as compared to the native molecule.
Help employers find you! Check out all the jobs and post your resume.
